Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199


AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression.

Ding K, Shen J, Hafiz Z, Hackett SF, Silva RLE, Khan M, Lorenc VE, Chen D, Chadha R, Zhang M, Van Everen S, Buss N, Fiscella M, Danos O, Campochiaro PA.

J Clin Invest. 2019 Aug 13;130:4901-4911. doi: 10.1172/JCI129085.


An Improved Adeno-Associated Virus Vector for Neurological Correction of the Mouse Model of Mucopolysaccharidosis IIIA.

Gray AL, O'Leary C, Liao A, Agúndez L, Youshani AS, Gleitz HF, Parker H, Taylor JT, Danos O, Hocquemiller M, Palomar N, Linden RM, Henckaerts E, Holley RJ, Bigger BW.

Hum Gene Ther. 2019 Sep;30(9):1052-1066. doi: 10.1089/hum.2018.189. Epub 2019 Jun 4.


RFX1 and RFX3 Transcription Factors Interact with the D Sequence of Adeno-Associated Virus Inverted Terminal Repeat and Regulate AAV Transduction.

Julien L, Chassagne J, Peccate C, Lorain S, Piétri-Rouxel F, Danos O, Benkhelifa-Ziyyat S.

Sci Rep. 2018 Jan 9;8(1):210. doi: 10.1038/s41598-017-18604-3.


Erratum: Lentiviral vectors can be used for full-length dystrophin gene therapy.

Counsell JR, Asgarian Z, Meng J, Ferrer V, Vink CA, Howe SJ, Waddington SN, Thrasher AJ, Muntoni F, Morgan JE, Danos O.

Sci Rep. 2017 Aug 29;7:46880. doi: 10.1038/srep46880.


Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing in Bone-Marrow-Derived CD34+ Hematopoietic Stem and Progenitor Cells.

Chang KH, Smith SE, Sullivan T, Chen K, Zhou Q, West JA, Liu M, Liu Y, Vieira BF, Sun C, Hong VP, Zhang M, Yang X, Reik A, Urnov FD, Rebar EJ, Holmes MC, Danos O, Jiang H, Tan S.

Mol Ther Methods Clin Dev. 2017 Jan 11;4:137-148. doi: 10.1016/j.omtm.2016.12.009. eCollection 2017 Mar 17.


Lentiviral vectors can be used for full-length dystrophin gene therapy.

Counsell JR, Asgarian Z, Meng J, Ferrer V, Vink CA, Howe SJ, Waddington SN, Thrasher AJ, Muntoni F, Morgan JE, Danos O.

Sci Rep. 2017 Mar 17;7:44775. doi: 10.1038/srep44775. Erratum in: Sci Rep. 2017 Aug 29;7:46880.


Lentiviral vectors can be used for full-length dystrophin gene therapy.

Counsell JR, Asgarian Z, Meng J, Ferrer V, Vink CA, Howe SJ, Waddington SN, Thrasher AJ, Muntoni F, Morgan JE, Danos O.

Sci Rep. 2017 Mar 6;7(1):79. doi: 10.1038/s41598-017-00152-5.


Meganuclease-Mediated COL7A1 Gene Correction for Recessive Dystrophic Epidermolysis Bullosa.

Izmiryan A, Danos O, Hovnanian A.

J Invest Dermatol. 2016 Apr;136(4):872-875. doi: 10.1016/j.jid.2015.11.028. Epub 2016 Feb 17. No abstract available.


Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy.

Meng J, Counsell JR, Reza M, Laval SH, Danos O, Thrasher A, Lochmüller H, Muntoni F, Morgan JE.

Sci Rep. 2016 Jan 27;6:19750. doi: 10.1038/srep19750.


Reply: To PMID 24332219.

van Til NP, Cortes P, Danos O, Cassani B, Poliani PL, Villa A, Wagemaker G.

J Allergy Clin Immunol. 2014 Jul;134(1):243-4. doi: 10.1016/j.jaci.2014.04.032. Epub 2014 Jun 26. No abstract available.


Lentiviral protein delivery of meganucleases in human cells mediates gene targeting and alleviates toxicity.

He C, Gouble A, Bourdel A, Manchev V, Poirot L, Paques F, Duchateau P, Edelman A, Danos O.

Gene Ther. 2014 Aug;21(8):759-66. doi: 10.1038/gt.2014.51. Epub 2014 Jun 12.


Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial.

Tardieu M, Zérah M, Husson B, de Bournonville S, Deiva K, Adamsbaum C, Vincent F, Hocquemiller M, Broissand C, Furlan V, Ballabio A, Fraldi A, Crystal RG, Baugnon T, Roujeau T, Heard JM, Danos O.

Hum Gene Ther. 2014 Jun;25(6):506-16. doi: 10.1089/hum.2013.238. Epub 2014 May 5.


Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome.

van Til NP, Sarwari R, Visser TP, Hauer J, Lagresle-Peyrou C, van der Velden G, Malshetty V, Cortes P, Jollet A, Danos O, Cassani B, Zhang F, Thrasher AJ, Fontana E, Poliani PL, Cavazzana M, Verstegen MM, Villa A, Wagemaker G.

J Allergy Clin Immunol. 2014 Apr;133(4):1116-23. doi: 10.1016/j.jaci.2013.10.009. Epub 2013 Dec 9.


Functional characterization of the human mariner transposon Hsmar2.

Gil E, Bosch A, Lampe D, Lizcano JM, Perales JC, Danos O, Chillon M.

PLoS One. 2013 Sep 11;8(9):e73227. doi: 10.1371/journal.pone.0073227. eCollection 2013.


Antisense oligonucleotides for therapeutic interventions in neuromuscular diseases.

Danos O.

Hum Gene Ther. 2013 May;24(5):470-1. doi: 10.1089/hum.2013.2504. No abstract available.


The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery.

Eckenfelder A, Tordo J, Babbs A, Davies KE, Goyenvalle A, Danos O.

Mol Ther Nucleic Acids. 2012 Jun 26;1:e31. doi: 10.1038/mtna.2012.24.


Comparative proteomic analysis of HIV-1 particles reveals a role for Ezrin and EHD4 in the Nef-dependent increase of virus infectivity.

Brégnard C, Zamborlini A, Leduc M, Chafey P, Camoin L, Saïb A, Benichou S, Danos O, Basmaciogullari S.

J Virol. 2013 Apr;87(7):3729-40. doi: 10.1128/JVI.02477-12. Epub 2013 Jan 16.


Suboptimal provirus expression explains apparent nonrandom cell coinfection with HIV-1.

Brégnard C, Pacini G, Danos O, Basmaciogullari S.

J Virol. 2012 Aug;86(16):8810-20. doi: 10.1128/JVI.00831-12. Epub 2012 Jun 13.


Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases.

Daboussi F, Zaslavskiy M, Poirot L, Loperfido M, Gouble A, Guyot V, Leduc S, Galetto R, Grizot S, Oficjalska D, Perez C, Delacôte F, Dupuy A, Chion-Sotinel I, Le Clerre D, Lebuhotel C, Danos O, Lemaire F, Oussedik K, Cédrone F, Epinat JC, Smith J, Yáñez-Muñoz RJ, Dickson G, Popplewell L, Koo T, VandenDriessche T, Chuah MK, Duclert A, Duchateau P, Pâques F.

Nucleic Acids Res. 2012 Jul;40(13):6367-79. Epub 2012 Mar 29.


Modeling the step of endosomal escape during cell infection by a nonenveloped virus.

Lagache T, Danos O, Holcman D.

Biophys J. 2012 Mar 7;102(5):980-9. doi: 10.1016/j.bpj.2011.12.037. Epub 2012 Mar 6.


Exploiting natural diversity of AAV for the design of vectors with novel properties.

Gao G, Zhong L, Danos O.

Methods Mol Biol. 2011;807:93-118. doi: 10.1007/978-1-61779-370-7_4.


Efficient gene targeting mediated by a lentiviral vector-associated meganuclease.

Izmiryan A, Basmaciogullari S, Henry A, Paques F, Danos O.

Nucleic Acids Res. 2011 Sep 1;39(17):7610-9. doi: 10.1093/nar/gkr524. Epub 2011 Jun 28.


Rescue of a dystrophin-like protein by exon skipping normalizes synaptic plasticity in the hippocampus of the mdx mouse.

Dallérac G, Perronnet C, Chagneau C, Leblanc-Veyrac P, Samson-Desvignes N, Peltekian E, Danos O, Garcia L, Laroche S, Billard JM, Vaillend C.

Neurobiol Dis. 2011 Sep;43(3):635-41. doi: 10.1016/j.nbd.2011.05.012. Epub 2011 May 23.


Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece.

Héron B, Mikaeloff Y, Froissart R, Caridade G, Maire I, Caillaud C, Levade T, Chabrol B, Feillet F, Ogier H, Valayannopoulos V, Michelakakis H, Zafeiriou D, Lavery L, Wraith E, Danos O, Heard JM, Tardieu M.

Am J Med Genet A. 2011 Jan;155A(1):58-68. doi: 10.1002/ajmg.a.33779.


Relevance of an academic GMP Pan-European vector infra-structure (PEVI).

Cohen-Haguenauer O, Creff N, Cruz P, Tunc C, Aïuti A, Baum C, Bosch F, Blomberg P, Cichutek K, Collins M, Danos O, Dehaut F, Federspiel M, Galun E, Garritsen H, Hauser H, Hildebrandt M, Klatzmann D, Merten OW, Montini E, O'Brien T, Panet A, Rasooly L, Scherman D, Schmidt M, Schweitzer M, Tiberghien P, Vandendriessche T, Ziehr H, Ylä-Herttuala S, von Kalle C, Gahrton G, Carrondo M.

Curr Gene Ther. 2010 Dec;10(6):414-22.


The compartmentalisation of phosphorylated free oligosaccharides in cells from a CDG Ig patient reveals a novel ER-to-cytosol translocation process.

Peric D, Durrant-Arico C, Delenda C, Dupré T, De Lonlay P, de Baulny HO, Pelatan C, Bader-Meunier B, Danos O, Chantret I, Moore SE.

PLoS One. 2010 Jul 20;5(7):e11675. doi: 10.1371/journal.pone.0011675.


The ARRIVE guidelines, a welcome improvement to standards for reporting animal research.

Danos O, Davies K, Lehn P, Mulligan R.

J Gene Med. 2010 Jul;12(7):559-60. doi: 10.1002/jgm.1472.


Rescue of a dystrophin-like protein by exon skipping in vivo restores GABAA-receptor clustering in the hippocampus of the mdx mouse.

Vaillend C, Perronnet C, Ros C, Gruszczynski C, Goyenvalle A, Laroche S, Danos O, Garcia L, Peltekian E.

Mol Ther. 2010 Sep;18(9):1683-8. doi: 10.1038/mt.2010.134. Epub 2010 Jun 29.


SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa.

Titeux M, Pendaries V, Zanta-Boussif MA, Décha A, Pironon N, Tonasso L, Mejia JE, Brice A, Danos O, Hovnanian A.

Mol Ther. 2010 Aug;18(8):1509-18. doi: 10.1038/mt.2010.91. Epub 2010 May 18.


Changes in the accessibility of the HIV-1 Integrase C-terminus in the presence of cellular proteins.

Benkhelifa-Ziyyat S, Bucher S, Zanta-Boussif MA, Pasquet J, Danos O.

Retrovirology. 2010 Apr 5;7:27. doi: 10.1186/1742-4690-7-27.


Antigen-specific Treg impair CD8(+) T-cell priming by blocking early T-cell expansion.

Chappert P, Leboeuf M, Rameau P, Lalfer M, Desbois S, Liblau RS, Danos O, Davoust JM, Gross DA.

Eur J Immunol. 2010 Feb;40(2):339-50. doi: 10.1002/eji.200839107.


Quantitative proteomic analysis of lentiviral vectors using 2-DE.

Denard J, Rundwasser S, Laroudie N, Gonnet F, Naldini L, Radrizzani M, Galy A, Merten OW, Danos O, Svinartchouk F.

Proteomics. 2009 Jul;9(14):3666-76. doi: 10.1002/pmic.200800747.


Diverse genomic integration of a lentiviral vector developed for the treatment of Wiskott-Aldrich syndrome.

Mantovani J, Charrier S, Eckenberg R, Saurin W, Danos O, Perea J, Galy A.

J Gene Med. 2009 Aug;11(8):645-54. doi: 10.1002/jgm.1346.


A comparison of synthetic oligodeoxynucleotides, DNA fragments and AAV-1 for targeted episomal and chromosomal gene repair.

Leclerc X, Danos O, Scherman D, Kichler A.

BMC Biotechnol. 2009 Apr 20;9:35. doi: 10.1186/1472-6750-9-35.


Evaluation of a Serum-free Medium for the Production of rAAV-2 using HeLa Derived Producer Cells.

Jenny C, Toublanc E, Danos O, Merten OW.

Cytotechnology. 2005 Sep;49(1):11-23. doi: 10.1007/s10616-005-5361-z.


AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis.

Buj-Bello A, Fougerousse F, Schwab Y, Messaddeq N, Spehner D, Pierson CR, Durand M, Kretz C, Danos O, Douar AM, Beggs AH, Schultz P, Montus M, Denèfle P, Mandel JL.

Hum Mol Genet. 2008 Jul 15;17(14):2132-43. doi: 10.1093/hmg/ddn112. Epub 2008 Apr 22.


AAV vectors for RNA-based modulation of gene expression.

Danos O.

Gene Ther. 2008 Jun;15(11):864-9. doi: 10.1038/gt.2008.69. Epub 2008 Apr 17. Review.


Efficient gene transfer in skeletal muscle with AAV-derived bicistronic vector using the FGF-1 IRES.

Delluc-Clavières A, Le Bec C, Van den Berghe L, Conte C, Allo V, Danos O, Prats AC.

Gene Ther. 2008 Aug;15(15):1090-8. doi: 10.1038/gt.2008.49. Epub 2008 Mar 27.


Recombination and population mosaic of a multifunctional viral gene, adeno-associated virus cap.

Takeuchi Y, Myers R, Danos O.

PLoS One. 2008 Feb 20;3(2):e1634. doi: 10.1371/journal.pone.0001634.


Mannosidase I inhibition rescues the human alpha-sarcoglycan R77C recurrent mutation.

Bartoli M, Gicquel E, Barrault L, Soheili T, Malissen M, Malissen B, Vincent-Lacaze N, Perez N, Udd B, Danos O, Richard I.

Hum Mol Genet. 2008 May 1;17(9):1214-21. doi: 10.1093/hmg/ddn029. Epub 2008 Feb 5.


Proteome analysis of differentiating human myoblasts by dialysis-assisted two-dimensional gel electrophoresis (DAGE).

Gonnet F, Bouazza B, Millot GA, Ziaei S, Garcia L, Butler-Browne GS, Mouly V, Tortajada J, Danos O, Svinartchouk F.

Proteomics. 2008 Jan;8(2):264-78. doi: 10.1002/pmic.200700261.


Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles.

Lorain S, Gross DA, Goyenvalle A, Danos O, Davoust J, Garcia L.

Mol Ther. 2008 Mar;16(3):541-7. doi: 10.1038/ Epub 2008 Jan 8.


Antigen-driven interactions with dendritic cells and expansion of Foxp3+ regulatory T cells occur in the absence of inflammatory signals.

Chappert P, Leboeuf M, Rameau P, Stockholm D, Liblau R, Danos O, Davoust JM, Gross DA.

J Immunol. 2008 Jan 1;180(1):327-34.


Safe selection of genetically manipulated human primary keratinocytes with very high growth potential using CD24.

Bergoglio V, Larcher F, Chevallier-Lagente O, Bernheim A, Danos O, Sarasin A, Rio MD, Magnaldo T.

Mol Ther. 2007 Dec;15(12):2186-93. Epub 2007 Aug 21.


Expression of mdr1 is required for efficient long term regeneration of dystrophic muscle.

Israeli D, Ziaei S, Gjata B, Benchaouir R, Rameau P, Marais T, Fukada S, Segawa M, Yamamoto H, Gonin P, Danos O, Garcia L.

Exp Cell Res. 2007 Jul 1;313(11):2438-50. Epub 2007 Apr 1.


AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency.

Bartoli M, Poupiot J, Vulin A, Fougerousse F, Arandel L, Daniele N, Roudaut C, Noulet F, Garcia L, Danos O, Richard I.

Gene Ther. 2007 May;14(9):733-40. Epub 2007 Mar 1.


Enhanced lentiviral transduction of monocyte-derived dendritic cells in the presence of conditioned medium from dying monocytes.

Masurier C, Boutin S, Veron P, Bernard J, Danos O, Davoust J.

Hum Gene Ther. 2007 Feb;18(2):161-70.


Optimising histidine rich peptides for efficient DNA delivery in the presence of serum.

Mason AJ, Leborgne C, Moulay G, Martinez A, Danos O, Bechinger B, Kichler A.

J Control Release. 2007 Mar 12;118(1):95-104. Epub 2006 Dec 8.


Phenotypic Correction of α-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector.

Fougerousse F, Bartoli M, Poupiot J, Arandel L, Durand M, Guerchet N, Gicquel E, Danos O, Richard I.

Mol Ther. 2007 Jan;15(1):53-61. doi: 10.1038/ Epub 2016 Dec 8.


Phenotypic correction of alpha-sarcoglycan deficiency by intra-arterial injection of a muscle-specific serotype 1 rAAV vector.

Fougerousse F, Bartoli M, Poupiot J, Arandel L, Durand M, Guerchet N, Gicquel E, Danos O, Richard I.

Mol Ther. 2007 Jan;15(1):53-61.

Supplemental Content

Support Center